Tags

Type your tag names separated by a space and hit enter

delta-Opioid receptor agonist SNC80 elicits peripheral antinociception via delta(1) and delta(2) receptors and activation of the l-arginine/nitric oxide/cyclic GMP pathway.
Life Sci. 2005 Nov 19; 78(1):54-60.LS

Abstract

In this study, we characterized the role of delta(1) and delta(2) opioids receptors, as well the involvement of the l-arginine/NO/cGMP pathway in the peripheral antinociception induced by delta-opioid receptor agonist (+)-4-[(alphaR)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC80). The paw pressure test was utilized, in which pain sensitivity is increased by intraplantar injection of prostaglandin E(2) (2 microg). Administration of SNC80 (20, 40 and 80 microg/paw) decreased the hyperalgesia induced by prostaglandin E(2) in a dose-dependent manner. The possibility that the higher dose of SNC80 (80 microg) has a central or systemic effect was excluded, since administration of the drug into the contralateral paw did not elicit antinociception in the right paw. 7-Benzylidenenaltrexone (BNTX), 5, 10 and 20 microg/paw, and 17-(Cyclopropylmethyl)-6,7-didehydro-3,14beta-dihydroxy-4,5alpha-epoxy-6,7-2',3'-benzo[b]furanomorphinan (naltriben), 2.5, 5 and 10 microg/paw, delta(1) and delta(2) opioid receptor antagonist respectively, elicited partial antagonism of the peripheral antinociceptive effect of the SNC80 (80 microg). The BNTX (10 microg/paw)-naltriben (5 microg/paw) combination completely antagonized the peripheral antinociception induced by SNC80 (80 microg). Further, blockers of the l-arginine/NO/cGMP pathway, N(G)-nitro-l-arginine (12, 18 and 24 microg/paw) and methylene blue (125, 250 and 500 microg/paw) were observed reverting the peripheral antinociceptive effect of SNC80. This study provides evidence that the peripheral antinociception induced by SNC80 occurs via delta(1) and delta(2) receptors and may result from l-arginine/NO/cGMP pathway activation.

Authors+Show Affiliations

Department of Pharmacology, Institute of Biological Sciences, UFMG, Av. Antônio Carlos, 6627, 31.270.100, Belo Horizonte, Brazil.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16135369

Citation

Pacheco, Daniela F., et al. "Delta-Opioid Receptor Agonist SNC80 Elicits Peripheral Antinociception Via Delta(1) and Delta(2) Receptors and Activation of the L-arginine/nitric Oxide/cyclic GMP Pathway." Life Sciences, vol. 78, no. 1, 2005, pp. 54-60.
Pacheco DF, Reis GM, Francischi JN, et al. Delta-Opioid receptor agonist SNC80 elicits peripheral antinociception via delta(1) and delta(2) receptors and activation of the l-arginine/nitric oxide/cyclic GMP pathway. Life Sci. 2005;78(1):54-60.
Pacheco, D. F., Reis, G. M., Francischi, J. N., Castro, M. S., Perez, A. C., & Duarte, I. D. (2005). Delta-Opioid receptor agonist SNC80 elicits peripheral antinociception via delta(1) and delta(2) receptors and activation of the l-arginine/nitric oxide/cyclic GMP pathway. Life Sciences, 78(1), 54-60.
Pacheco DF, et al. Delta-Opioid Receptor Agonist SNC80 Elicits Peripheral Antinociception Via Delta(1) and Delta(2) Receptors and Activation of the L-arginine/nitric Oxide/cyclic GMP Pathway. Life Sci. 2005 Nov 19;78(1):54-60. PubMed PMID: 16135369.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - delta-Opioid receptor agonist SNC80 elicits peripheral antinociception via delta(1) and delta(2) receptors and activation of the l-arginine/nitric oxide/cyclic GMP pathway. AU - Pacheco,Daniela F, AU - Reis,Gláucia M L, AU - Francischi,Janetti N, AU - Castro,Maria S A, AU - Perez,Andrea C, AU - Duarte,Igor D G, Y1 - 2005/08/29/ PY - 2004/10/13/received PY - 2005/04/05/accepted PY - 2005/9/2/pubmed PY - 2005/12/15/medline PY - 2005/9/2/entrez SP - 54 EP - 60 JF - Life sciences JO - Life Sci VL - 78 IS - 1 N2 - In this study, we characterized the role of delta(1) and delta(2) opioids receptors, as well the involvement of the l-arginine/NO/cGMP pathway in the peripheral antinociception induced by delta-opioid receptor agonist (+)-4-[(alphaR)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC80). The paw pressure test was utilized, in which pain sensitivity is increased by intraplantar injection of prostaglandin E(2) (2 microg). Administration of SNC80 (20, 40 and 80 microg/paw) decreased the hyperalgesia induced by prostaglandin E(2) in a dose-dependent manner. The possibility that the higher dose of SNC80 (80 microg) has a central or systemic effect was excluded, since administration of the drug into the contralateral paw did not elicit antinociception in the right paw. 7-Benzylidenenaltrexone (BNTX), 5, 10 and 20 microg/paw, and 17-(Cyclopropylmethyl)-6,7-didehydro-3,14beta-dihydroxy-4,5alpha-epoxy-6,7-2',3'-benzo[b]furanomorphinan (naltriben), 2.5, 5 and 10 microg/paw, delta(1) and delta(2) opioid receptor antagonist respectively, elicited partial antagonism of the peripheral antinociceptive effect of the SNC80 (80 microg). The BNTX (10 microg/paw)-naltriben (5 microg/paw) combination completely antagonized the peripheral antinociception induced by SNC80 (80 microg). Further, blockers of the l-arginine/NO/cGMP pathway, N(G)-nitro-l-arginine (12, 18 and 24 microg/paw) and methylene blue (125, 250 and 500 microg/paw) were observed reverting the peripheral antinociceptive effect of SNC80. This study provides evidence that the peripheral antinociception induced by SNC80 occurs via delta(1) and delta(2) receptors and may result from l-arginine/NO/cGMP pathway activation. SN - 0024-3205 UR - https://www.unboundmedicine.com/medline/citation/16135369/delta_Opioid_receptor_agonist_SNC80_elicits_peripheral_antinociception_via_delta_1__and_delta_2__receptors_and_activation_of_the_l_arginine/nitric_oxide/cyclic_GMP_pathway_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0024-3205(05)00669-7 DB - PRIME DP - Unbound Medicine ER -